Viewing Study NCT06514118



Ignite Creation Date: 2024-10-26 @ 3:35 PM
Last Modification Date: 2024-10-26 @ 3:35 PM
Study NCT ID: NCT06514118
Status: RECRUITING
Last Update Posted: None
First Post: 2024-07-04

Brief Title: Chemoimmunotherapy Plus Residual Lesion Irradiation for the Treatment of Extensive Stage Small-cell Lung Cancer
Sponsor: None
Organization: None

Study Overview

Official Title: Chemoimmunotherapy Plus Ratiotherapy for Extensive Stage Small-cell Lung Cancer
Status: RECRUITING
Status Verified Date: 2024-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This is a phase II trial studies the effect of chemoimmunotherapy sequential residual tumor irradiation in treating patients with extensive stage small cell lung cancer Even though small cell lung cancer is initially highly responsive to first-line chemotherapy plus PD-L1 inhibitors treatment resistance inevitably happens Residual tumor irradiation my prolong drug resistance and may help prevent the growth and spread of the tumor cells to other parts of the body
Detailed Description: PRIMARY OBJECTIVE

I To evaluate the progression-free survival PFS and overall survival of chemoimmunotherapy sequential residual tumor irradiation in patients with extensive stage small cell lung cancer SCLC

SECONDARY OBJECTIVES

II To assess the overall response rate ORR and toxicity in extensive stage SCLC patients treated with chemoimmunotherapy squential residual tumor irradiation

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None